Medikaloka Hermina Yönetim

Yönetim kriter kontrolleri 2/4

Medikaloka Hermina CEO'su H. Hasmoro, Jan1991 tarihinde atandı, in görev süresi 33.83 yıldır. şirketin hisselerinin 4.86% doğrudan sahiptir ve bu hisselerin değeri IDR 1,021.33B dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 6.8 yıldır.

Anahtar bilgiler

H. Hasmoro

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	33.8yrs
CEO sahipliği	4.9%
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

H. Hasmoro (80 yo)

33.8yrs

Görev süresi

Dr. H. Hasmoro, Sp An, KIC, MHA, MM, has been President Director of PT Medikaloka Hermina Tbk since 1991. Previously, Dr. Hasmoro served as Member of Presidential Specialist Team from 1987 to 2000.He join...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
H. Hasmoro	President Director	33.8yrs	Veri yok	4.86% IDR 1.0t
Yulisar Khiat	MD of Finance & Strategic Development and Director	less than a year	Veri yok	13.02% IDR 2.7t
Tan Gunadi	MD of Operational & General Affairs and Director	less than a year	Veri yok	Veri yok
Binsar Simorangkir	MD of Medical and Compliance & Director	no data	Veri yok	5.51% IDR 1.2t
Arie Wahyudi	Head of Licensing & Legal	no data	Veri yok	Veri yok
Muyi Hapsari	Head of Marketing	no data	Veri yok	Veri yok
Susi Setiawaty	MD of Human Capital	4.2yrs	Veri yok	Veri yok
Meijani Wibowo	Commissioner	no data	Veri yok	2.21% IDR 464.9b
Hastiyudo Wibowo	Business Development	no data	Veri yok	Veri yok
Chatarina Sri Marsiyo	Head of Internal Audit	4.2yrs	Veri yok	Veri yok
Yuyun Gunaedi	Information Technology	no data	Veri yok	Veri yok

4.2yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim: HEAL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
H. Hasmoro	President Director	33.8yrs	Veri yok	4.86% IDR 1.0t
Yulisar Khiat	MD of Finance & Strategic Development and Director	27.8yrs	Veri yok	13.02% IDR 2.7t
Tan Gunadi	MD of Operational & General Affairs and Director	less than a year	Veri yok	Veri yok
Binsar Simorangkir	MD of Medical and Compliance & Director	26.8yrs	Veri yok	5.51% IDR 1.2t
Susi Setiawaty	MD of Human Capital	less than a year	Veri yok	Veri yok
Meijani Wibowo	Commissioner	2.8yrs	Veri yok	2.21% IDR 464.9b
Amit Varma	Independent Commissioner	4.8yrs	Veri yok	Veri yok
Alexander Rusli	Independent Commissioner	6.8yrs	Veri yok	Veri yok
Darwin Noerhadi	Commissioner	7.8yrs	Veri yok	Veri yok
Husen Sutakaria	Vice President Commissioner	6.8yrs	Veri yok	2.85% IDR 597.4b
Paulus Gunawan	President Commissioner	7.8yrs	Veri yok	Veri yok
. Heridadi	Independent Commissioner	6.8yrs	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HEAL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

Medikaloka Hermina Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Key Executive recently bought Rp4.5b worth of stock

Key Executive recently bought Rp109b worth of stock

President Director recently bought Rp5.0b worth of stock

President Director recently bought Rp8.3b worth of stock

President Director recently bought Rp308m worth of stock

Key Executive recently bought Rp687m worth of stock

Recent updates

Key Executive recently bought Rp4.5b worth of stock

Third quarter 2024 earnings released: EPS: Rp8.39 (vs Rp10.11 in 3Q 2023)

Key Executive recently bought Rp109b worth of stock

President Director recently bought Rp5.0b worth of stock

Second quarter 2024 earnings released: EPS: Rp10.25 (vs Rp6.45 in 2Q 2023)

President Director recently bought Rp8.3b worth of stock

Consensus EPS estimates increase by 13%

Investor sentiment improves as stock rises 17%

Now 20% overvalued

First quarter 2024 earnings released: EPS: Rp12.96 (vs Rp7.52 in 1Q 2023)

Full year 2023 earnings released: EPS: Rp30.16 (vs Rp20.64 in FY 2022)

New minor risk - Shareholder dilution

President Director recently bought Rp308m worth of stock

Key Executive recently bought Rp687m worth of stock

Third quarter 2023 earnings released: EPS: Rp10.12 (vs Rp5.61 in 3Q 2022)

Key Executive recently bought Rp12b worth of stock

Second quarter 2023 earnings released: EPS: Rp6.45 (vs Rp3.68 in 2Q 2022)

Price target increased to Rp2,170

Less than half of directors are independent

Consensus EPS estimates fall by 17%

PT Medikaloka Hermina Tbk Ordinary Shares to Be Deleted from OTC Equity

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target increased to Rp1,427

Consensus EPS estimates fall by 15%

Less than half of directors are independent

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

PT Medikaloka Hermina Tbk (IDX:HEAL) announces an Equity Buyback for 80,000,000 shares, for IDR 116,000 million.

Third quarter 2021 earnings released: EPS Rp15.57 (vs Rp10.64 in 3Q 2020)

Price target increased to Rp1,255

Second quarter 2021 earnings released

Consensus EPS estimates increase to Rp50.58

Investor sentiment improved over the past week

Consensus EPS estimates increase to Rp222

Price target increased to Rp5,756

First quarter 2021 earnings released: EPS Rp95.79 (vs Rp24.16 in 1Q 2020)

Price target increased to Rp5,150

Consensus EPS estimates increase to Rp173

Price target increased to Rp4,959

Consensus EPS estimates increase to Rp160

New 90-day high: Rp4,200

New 90-day high: Rp4,000

New 90-day high: Rp3,930

Analysts update estimates

Price target raised to Rp4,368

New 90-day high: Rp3,450

Third quarter 2020 earnings released: EPS Rp53.13

First half earnings released

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş